Inmune Bio Inc. (INMB)
| Market Cap | 122.21M |
| Revenue (ttm) | 340,000 |
| Net Income (ttm) | -32.69M |
| Shares Out | 17.95M |
| EPS (ttm) | -1.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 164,560 |
| Open | 6.43 |
| Previous Close | 6.33 |
| Day's Range | 6.33 - 7.00 |
| 52-Week Range | 4.63 - 30.37 |
| Beta | 2.44 |
| Analysts | Buy |
| Price Target | 22.78 (+234.5%) |
| Earnings Date | May 5, 2022 |
About INMB
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; a...
Financial Performance
In 2021, Inmune Bio's revenue was $181,000, an increase of 1,545.45% compared to the previous year's $11,000. Losses were -$30.34 million, 150.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for INMB stock is "Buy." The 12-month stock price forecast is 22.78, which is an increase of 234.51% from the latest price.
News
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study
The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.
INmune Bio stock plunges after clinical hold of IND of Alzheimer's treatment prompts analyst downgrade
Shares of INmune Bio Inc. INMB, -1.09% plummeted 31.4% toward a 22-month low in premarket trading Tuesday, after the Florida-based biotechnology company said it received an email from U.S. Food and Drug...
INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595™ in A...
BOCA RATON, FL., May 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate...
INmune Bio, Inc. to Present at the H.C. Wainwright Global Hybrid Investment Conference on May 24th
Boca Raton, FL, May 18, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient's immune system to fight disease...
INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray Matter at 3rd European Conference o...
XPro™ Promotes Remyelination in a Cuprizone Model of Multiple Sclerosis(MS) by Improving Macrophage Phagocytosis (clearing) of Myelin Debris
INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update
Company Dosed First Phase 2 Mild Alzheimer's Disease Patient with Xpro1595; Presented Data from Ongoing INKmune™ Studies Suggesting Increased NK Cell Treatment Effective Against Solid Malignancies
INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5
Management to host conference call and webcast at 4:30 pm ET on that day Management to host conference call and webcast at 4:30 pm ET on that day
INmune Bio, Inc. to Participate at the B. Riley Neuro & Ophthalmology Conference
Boca Raton, FL, April 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient's immune system to fight disea...
INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate
INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.
INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of A...
INmune Bio Plans to Enroll 201 Patients in a 6-Month Study to Evaluate Cognitive Function in Patients with Mild Alzheimer's Disease INmune Bio Plans to Enroll 201 Patients in a 6-Month Study to Evaluate...
INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research (AACR) Annual M...
Data from animal models of trastuzumab-resistant MUC4 HER2+ breast cancer show that treatment with INB03 decreases MUC4 expression, reverses resistance to trastuzumab and tyrosine kinase inhibitors, and...
INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit
INKmune™, unlike IL15 and other NK-activating cytokines, upregulates all mitochondrial survival proteins and more than 40 nutrient receptors on the NK cell to increase survival
INmune Bio, Inc. Announces Company's CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumors” Workshop at Innat...
The Company also Plans on Sharing INKmune™ Patient Case Studies The Company also Plans on Sharing INKmune™ Patient Case Studies
INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022
International Conference on Alzheimer's and Parkinson's Diseases Provides New Insights into the Role of Neuroinflammation in AD and the Promise of Xpro™ for Treatment International Conference on Alzheim...
INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 - International Conference on Alzheimer's and Parki...
Conference Provides First Exposure of EU and UK AD Experts to INmune Bio's Approach of Targeting Neuroinflammation and Glial Activation with XPro™ for Treatment of Alzheimer's Disease
INmune Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual...
Boca Raton, FL, March 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient's immune system to fight disea...
INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business Update
Opens Phase 2 mild Alzheimer's trial and reports positive patient data from ongoing INKmuneTM trial in patient with high-risk myelodysplastic syndrome Opens Phase 2 mild Alzheimer's trial and reports po...
INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3
Management to host conference call and webcast at 4:30 pm ET on that day
INmune Bio, Inc. to Present at the BIO CEO & Investor Conference
BOCA RATON, Florida., Feb. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's ...
INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopha...
Boca Raton, Florida, Jan. 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the ...
INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting
Boca Raton, Florida, Jan. 04, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's ...
INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 San Antonio Breast...
Data suggests in triple negative breast cancer that MUC4 predicts survival and resistance to immunotherapy and that INB03 reverses resistance by decreasing immunosuppression in the TME
INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day ...
Boca Raton, Florida, Dec. 01, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's in...
INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update
Announces second Phase 2 trial of XPro in Mild Cognitive Impairment (MCI) in addition to previously announced Phase 2 trial in mild Alzheimer's disease (AD)
INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimer's Disease ...
Boca Raton, Florida, Oct. 27, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's ...